首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:The lancet regional health southeast asia

缩写:

ISSN:2772-3682

e-ISSN:2772-3682

IF/分区:6.4/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引742条
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Minh D Pham,Susan M Sawyer,Paul A Agius et al. Minh D Pham et al.
Background: Adolescence is a development period marked by the onset of a new set of health needs. The present study sought to quantify the prevalence of foregone care (not seeking medical care when needed) and identify wh...
S Manikandan S Manikandan
India recently released its fifth National List of Essential Medicines 2022 (NLEM 2022). A critical analysis of the list was performed and was compared with the WHO 22nd Model List of Essential Medicines published in 2021. The Standing Nati...
Kinanti Khansa Chavarina,Dian Faradiba,Ella Nanda Sari et al. Kinanti Khansa Chavarina et al.
Background: The Government of Indonesia implemented health technology assessment (HTA) to ensure quality and cost control in the National Health Insurance Program (Jaminan Kesehatan Nasional/JKN). The current aim of the s...
Nachiket Mor,Sudheer Kumar Shukla Nachiket Mor
Background: Universal Health Coverage (UHC) has been high on national and international agendas since its adoption as one of the Sustainable Development Goals (SDGs). Within India, there is a wide variation in the total a...
Sweta Dubey,Swasti Deshpande,Lokesh Krishna et al. Sweta Dubey et al.
India has run multiple Government-Funded Health Insurance schemes (GFHIS) over the past decades to ensure affordable healthcare. We assessed GFHIS evolution with a special focus on two national schemes - Rashtriya Swasthya Bima Yojana (RSBY...
Prerika Nehra,Akashdeep Singh Chauhan,Pankaj Malhotra et al. Prerika Nehra et al.
Background: Over the years, there has been introduction of newer drugs, like bendamustine and ibrutinib, for the management of chronic lymphocytic leukaemia (CLL). Though these drugs lead to better survival, they are also...